Save the PDF to draw one Owl Card (per stock, once a day)
OWL LABS EQUITY RESEARCH
MCK · SIGNATURE REPORT OWL-260729-MCK · JULY 29, 2026
SIGNATURE QUANT PROFILE · HEALTH CARE
McKesson Corporation MCK · NYSE
Health Care · USD listed
OWL VERDICT
CAUTIOUS
Grade C · Score 53 / 100
LAST PRICE
$889.5
▲ +4.6%
OWL FAIR VALUE
$911.66
+2.5% vs price
STREET TARGET
$941.4
+5.8% · 15 analysts
MARKET CAP
$104.1B
div yield 0.37%
P/E · P/B
22.2 · -49.1
ROIC 7.8%
52-WEEK RANGE
637.0–999.0
now at 70th pctile
Investment Summary
01
Quality vs. price, measured. Quality axes (ROIC 7.8%, op. margin 1.6%) score 8/40; value axes (P/E 22.2x, P/B -49.14x, EV/EBITDA, dividend) score 37/80. The composite 53/100 (grade C) is that arithmetic. Book equity is distorted by buybacks, so profitability is read via ROIC, not ROE.
02
Smart money holds. 1 of 9 tracked 13F managers hold MCK — 0 adding, 1 trimming this quarter. Filed positions, not opinions (details p.3).
03
0 of 5 value strategies pass. No mechanical screen admits MCK; the other 5 reject on their coded rules (details p.2).
04
What would change this report. Model fair value is $911.66 (+2.5% vs price); The verdict changes only when the data changes — screening reruns every weekday.
THE OWL VIEW
The composite lands mid-range: 53/100 — 0/5 value screens pass; 1 of 9 tracked managers hold. We grade MCK C — Cautious: the data supports watching, not chasing, at current measurements.
This report aggregates Owl Labs quant modules — 7-axis screener, 5 value strategies, 9 guru 13F filings, fair-value model, technical signals and news. All figures are measured from data sources as of the date above; sentences are rule-based templates (no generative claims). The score is a fitness test of reported fundamentals against today’s price — a screener, not a forecast; forward growth is not part of the score. Not investment advice.
MCK · SIGNATURE REPORT OWL-260729-MCK · JULY 29, 2026
Valuation — Five Value Disciplines
SECTION 02 OF 5
Each strategy is a mechanical screen coded from the discipline's published rules — a stock either passes or it does not. MCK passes 0 of 5. Verdicts are computed, not opined; the measured inputs are shown for audit.
STRATEGY
MECHANICAL CRITERIA
VERDICT
MEASURED INPUTS
Graham Defensive
Low P/E × low P/B composite screen
FAIL
P/E×P/B -1089
Greenblatt Magic Formula
Earnings yield + return on capital, top 30%
FAIL
E/P 4.5% · ROE -219.2%
Prasad Deep Value
Low P/B, low leverage, positive earnings
FAIL
P/B -49.14x
Simple DCF
OWL LABS EQUITY RESEARCH
MCK · SIGNATURE REPORT OWL-260729-MCK · JULY 29, 2026
Smart-Money Positioning — 9 Tracked Managers
SECTION 03 OF 5
Holdings from SEC 13F filings (latest period 2026-03-31; filed ~45 days after quarter end — stale by design). Weight = % of the manager's disclosed US long book. 1 of 9 managers hold MCK. These are filed positions — not the managers' opinions on this stock.
MANAGER
FUND
STYLE
WEIGHT
ACTION
STYLE LENS (RULE-BASED)
Warren Buffett
Berkshire Hathaway Inc.
Value
—
NO POSITION
Value lens: P/E 22.2x · P/B -49.14x
Ray Dalio
Bridgewater Associates, LP
Macro
0.3%
TRIMMED
0.3% of disclosed book · $58M
OWL LABS EQUITY RESEARCH
MCK · SIGNATURE REPORT OWL-260729-MCK · JULY 29, 2026
Tape, Catalysts & Risk Register
SECTION 04 OF 5
Technical Readout as of Tue Jul 28
RSI (14d)71.6 — overbought
MACD vs signal+5.63 above
MA20 / MA60$814.65 / $779.88
Cross stateNone
Distance to 52-wk high-11.0%
52-wk range position70th percentile
Day change+4.6%
OWL LABS EQUITY RESEARCH
MCK · SIGNATURE REPORT OWL-260729-MCK · JULY 29, 2026
Financial Record & Final Judgment
SECTION 05 OF 5
FISCAL YEAR
FY2024
FY2025
FY2026
Revenue
$309.0B
$359.1B
$403.4B
Operating income
$4.2B
$4.8B
$6.5B
Net income
$3.0B
$3.3B
$4.8B
Op. margin
1.4%
1.3%
1.6%
Net margin
1.0%
0.9%
1.2%
ROE
-152.3%
-158.9%
-219.2%
8/20
Op. margin
0/20
EV/EBIT
12/20
Dividend
3/20
Attention
17/20
Composite (incl. adj.)53 / 100 · C
US universe rank#395 of 623 · top 63%
Value screens passed0 / 5
52-wk range position70%
Next earningsTBA
Axis weights are proprietary; axis names and raw scores are disclosed. Attention measures news & search interest — a crowding proxy, not a quality signal.
One-line read: Health Care name scoring 53/100 (grade C), passing 0/5 value strategies, held by 1 of 9 tracked gurus.
Conservative discounted cash flow vs price
FAIL
Model $911.66 vs $889.5
Damodaran Relative
Multiples vs sector median, growth-adjusted
FAIL
P/E 22.2x · rev +12.4%
Fair-Value Bridge method blend, measured
Growth/quality-adjusted PER (w20%)$792.7
Analyst target (15) (w80%)$941.4
Owl fair value / share$911.66
Upside at $889.5+2.5%
MODEL INPUTS (DISCLOSED)
P/E · P/B22.2x · -49.14x
ROE (latest FY)-219.2%
ROE (3-yr avg, normalized)-176.8%
Revenue CAGR (2-yr)+14.3%
Band: FAIR · justified-multiple model with quality/growth adjustments — an estimate, not a promise.
Sensitivity value per share
EARNINGS ↓ / MULTIPLE →
-10%
base
+10%
-10%
$642.09
$713.43
$784.77
base (measured)
$713.43
$792.7
$871.97
+10%
$784.77
$871.97
$959.16
Simple sensitivity (reference): ±10% arithmetic on the measured P/E-method value — earnings basis × fair multiple. Not a forecast; no projected figures are used.
Read this like a memo: the model says $911.66 and the Street consensus says $941.4 (15 analysts). The gap is the assumption set — both are computed from disclosed inputs above; underwrite the difference yourself.
Information only — not investment advice · Sources: exchange data · SEC EDGAR · DART · Owl Labs models
1 of 9 tracked managers hold MCK; net flow skews to distribution (1 trimming vs 0 adding). These are filed positions, not opinions — the lens column restates each manager's public style against measured metrics only.
13F filings disclose US-listed long positions ~45 days after quarter end (latest period: 2026-03-31). "Style lens" lines relate this stock to each investor's public style using measured metrics only — they are not the managers' actual views.
Information only — not investment advice · Sources: exchange data · SEC EDGAR · DART · Owl Labs models
Measured state: RSI 71.6 (overbought), MACD above its signal, no MA cross is active. Read the tape as one input, not a verdict.
Catalyst Calendar
No confirmed earnings date in calendar
Every weekday — quant screening refreshscore update
Quarterly — 13F filing window (~45d after quarter end)13F refresh
Forward Signals (unscored) consensus data · never scored
Street target consensus$941.4 (15)
Implied upside vs price+5.8%
Next-quarter EPS estimate—
Next-quarter revenue estimate—
Shown for context, never scored: the composite grades only reported fundamentals. Forward numbers are third-party consensus — treat them as the market’s assumption set, not ours.
Risk Register
QUANT
Crowding. Attention axis 17/20 — elevated news & search interest (a crowding proxy, not a quality signal).
WHAT THE BEARS MUST PROVE / WHAT THE BULLS MUST PROVE
Bears: that the measured quality base cracks — ROE -219.2% and op. margin 1.6% are what the score leans on. Bulls: less on price — the model's $911.66 sits +2.5% above; they must show the measured fundamentals hold through the next filings.
Information only — not investment advice · Sources: exchange data · SEC EDGAR · DART · Owl Labs models
07/25 — McKesson (MCK) Stock May Still Be A Bargain After A 324% Run (Yahoo Finance Singapore)
07/25 — Rising Dividend and Buybacks Might Change The Case For Investing In McKesson (MCK) (Yahoo Finance)
External media — accuracy rests with each outlet.
Methodology & how to use
Every number in this report is measured — pulled from the screener database, SEC EDGAR 13F filings, DART disclosures, company financials, or deterministic models (justified-multiple fair value). Sentences are rule-based templates bound to those numbers; nothing is generated, so nothing is hallucinated. Axis weights and the sector adjustment are proprietary; axis names, raw scores, and every input above are disclosed for audit.
Known limits, stated plainly. ① Backward-looking — the score grades reported fundamentals and today's price; future inflections (a cycle turn, next year's earnings) are not scored and appear only as unscored context (street target, catalysts). A low score can mean "great business, full price". ② The composite is this framework's ranking, not an absolute quality of the company. ③ 13F covers US-listed holdings only. Use the report as a screener; pair it with your own forward and qualitative work before acting.
C
CAUTIOUS
Final judgment. MCK scores 53/100 (grade C) — rank #395 of 623 in the US universe. Axis split: quality 8/40 · value 37/80 · attention 17/20. Model fair value $911.66 (+2.5% vs price). The verdict changes only when the data changes.
Grade rubric: A 85+ (top conviction basket) · B 65+ (sound, price matters) · C 45+ (no rush) · D below (weak case). The verdict changes only when the data changes — next screening runs every weekday.
Owl Labs is an online information provider. This document is compiled from public data sources (exchange quotes, SEC EDGAR 13F, DART filings, company financials, news RSS) and Owl Labs quantitative models. It is not investment advice, not a solicitation to trade any security, and past data does not guarantee future results. Figures may differ from real-time values. Final investment decisions and responsibility rest solely with the investor. Unauthorized redistribution prohibited.
